1 / 7

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Am Heart J. 2003 Aug;146(2):304-10. EVET.

meryle
Download Presentation

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes:The EVET Trial Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Am Heart J. 2003 Aug;146(2):304-10

  2. EVET 438 patients with non-ST-segment elevation acute coronary syndromes (NSTACS) Single center, open-label randomized trial • Enoxaparin • Subcutaneous 100 IU/kg 2x daily • Equivalent to 1 mg/kg 2x daily • (n = 220) • Tinzaparin • 175 IU/kg once daily • (n = 218) • Endpoints: • Primary – Composite of recurrent angina, MI or death at day 7 • Secondary – Primary endpoint at day 30 and the individual events at days 7 and 30 Am Heart J 2003;146(2):304-10

  3. EVET: Primary Composite Endpoint at Day 7 Death, MI, Recurrent Angina p=0.015 % Am Heart J 2003;146(2):304-10

  4. EVET: Components of Composite Endpoint at Day 7 Recurrent Angina p<0.05 Death p=NS MI p=NS % Am Heart J 2003;146(2):304-10

  5. EVET: Primary Composite Endpoint at Day 30 Death, MI, Recurrent Angina p=0.012 % Am Heart J 2003;146(2):304-10

  6. EVET: Components of Composite Endpoint Day 30 Recurrent Angina p<0.05 Death p=NS MI p<0.05 % Am Heart J 2003;146(2):304-10

  7. EVET: Revascularization at Day 7 and Day 30 Day 30 p=0.019 Day 7 p=0.010 % Am Heart J 2003;146(2):304-10

More Related